These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12819293)

  • 1. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
    Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
    Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing a fateful alliance: anaemia and cardiovascular outcomes.
    Eckardt KU
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi16-20. PubMed ID: 15958821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS
    Semin Dial; 2005; 18(1):22-9. PubMed ID: 15663760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Achieving therapeutic targets in renal anaemia: considering cost-efficacy.
    Deray G
    Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of anaemia management in renal insufficiency and cardiac disease.
    Silverberg D
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii7-12. PubMed ID: 12819294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study.
    Schiller B; Doss S; DE Cock E; Del Aguila MA; Nissenson AR
    Hemodial Int; 2008 Oct; 12(4):441-9. PubMed ID: 19090867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
    Wong CF; McCarthy M; Howse ML; Williams PS
    Ren Fail; 2007; 29(6):653-9. PubMed ID: 17763158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
    Macdougall IC; Temple RM; Kwan JT
    Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
    Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
    Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
    Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug usage evaluation of epoetin in chronic renal failure.
    Mason NA; Iacobellis DP
    Hosp Formul; 1992 Sep; 27(9):928-32, 937-8. PubMed ID: 10121421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of anemia in clinic patients with heart failure and cost analysis of epoetin treatment.
    Choy CK; Spencer AP; Nappi JM
    Pharmacotherapy; 2007 May; 27(5):707-14. PubMed ID: 17461706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
    Jacobs C; Frei D; Perkins AC
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs.
    Wei SY; Chang YY; Mau LW; Lin MY; Chiu HC; Tsai JC; Huang CJ; Chen HC; Hwang SJ
    Nephrology (Carlton); 2010 Feb; 15(1):108-15. PubMed ID: 20377778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of an ambulatory program devoted to chronic renal insufficiency on the reduction of mobidity and hospitalization among patients at the beginning of dialysis treatment].
    Malberti F; Ravani P
    G Ital Nefrol; 2003; 20(2):127-32. PubMed ID: 12746797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.